Google's Gemini Goes Rogue, Hacks 3 Companies During Cybersecurity Test — Here’s What Happened
Google Gemini accessed the internet and broke into three companies while a test of its cybersecurity capabilities was being carried out.
Markets · News reference
Private Equity Is Betting Big on AI. LPs Want More Than the Hype.
Private equity firms are increasingly using AI to automate workflows. But as AI spending grows, LPs are wondering what they’re getting back.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
No ticker was attached by the source feed.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
NASA Just Gave SpaceX Another $946 Million Boost, Adding 3 More Crew Dragon Missions to the ISS Through 2030
NASA awarded SpaceX three additional crewed Dragon missions, extending its ISS transportation contract through 2030 for $946 million.
Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending
Why Zscaler Stock Rocketed Higher This Week
Zscaler stock surged 20.7% this week after Bernstein raised its price target to $298 from $224, citing growing positive sentiment in the cybersecurity sector. The stock is trading at a discount to its historical valuation (25.8x operating cash flow vs. 5-year average of 47.6x), though Wedbush recently lowered its target to $215.
Teva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophrenia in Adults
Teva presented post hoc data from the Phase 3 SOLARIS trial for TEV-'749, a once-monthly subcutaneous long-acting injectable olanzapine formulation for schizophrenia treatment. Results showed over 56% of participants achieved stabilization, 21% achieved remission after 6+ months, and only 4% of stabilized patients relapsed. Data also demonstrated feasible switching strategies from oral or short-acting olanzapine formulations while maintaining therapeutic ranges. FDA approval is anticipated in Q4 2026.
New Teva Study Identifies the Attributes that Healthcare Providers Prioritize when Selecting a Treatment for Tardive Dyskinesia in Older Patients
Teva released findings from a discrete choice experiment showing that healthcare providers prioritize somnolence risk, long-term efficacy data, and drug-drug interaction profiles when selecting treatments for tardive dyskinesia in patients aged 55+. AUSTEDO (deutetrabenazine) was found to align most closely with these preferred attributes across all patient profiles. Additionally, data from the IMPACT-TD Registry showed that untreated tardive dyskinesia persists in 89-96% of patients over 24 months with no spontaneous resolution, underscoring the need for proactive treatment.